In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.

CELMoDs are being actively trialed as a maintenance therapy after CAR T-cell treatment. The strategy is to leverage the CELMoDs' ability to enhance T-cell function and upregulate effector T-cells to boost the activity and persistence of the CAR-T product, potentially leading to more durable responses and preventing relapse.

Clinicians must weigh the immediate benefit of using community-accessible belantumab against the risk of reducing the efficacy of future BCMA-targeted therapies like CAR-T or bispecifics. This decision hinges on a patient's ability to travel and access advanced care, creating a complex treatment sequencing challenge.

The DREAM-7 trial showed a belantumab combination had an overall survival benefit versus a daratumumab regimen, a "premier drug" that previously changed the myeloma treatment landscape. This surprising result establishes a new, higher standard of care and positions belantumab as a top-tier therapy, not merely another option.

Unlike older IMiDs where T-cell effects are secondary, CELMoDs have a powerful, independent pro-T-cell mechanism. This dual action is so significant that in the future, CELMoDs will be prescribed not just for their direct anti-myeloma effects, but specifically to enhance the efficacy of T-cell therapies like CAR-T and bispecific antibodies.

Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.

In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.

Belantamab's primary mechanism, immunogenic cell death, does not exhaust T-cells. This unique quality allows clinicians to use it as a first BCMA-targeted agent without compromising the efficacy of subsequent T-cell redirecting therapies like CAR T or bispecifics.

Five-year follow-up from the CARTITUDE-1 trial suggests a potential cure for multiple myeloma is achievable. With roughly one-third of heavily pretreated patients remaining in remission at five years—and some confirmed as MRD-negative—the concept of a cure is now part of the operational discussion among specialists, a monumental shift for a disease long considered incurable.